{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:31:40Z","timestamp":1790242300873,"version":"4.1.0"},"reference-count":165,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EH 192\/5-3"],"award-info":[{"award-number":["EH 192\/5-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Adenoviral vectors (AdVs) have attracted much attention in the fields of vaccine development and treatment for diseases such as genetic disorders and cancer. In this review, we discuss the utility of AdVs in cancer therapies. In recent years, AdVs were modified as oncolytic AdVs (OAs) that possess the characteristics of cancer cell-specific replication and killing. Different carriers such as diverse cells and extracellular vesicles are being explored for delivering OAs into cancer sites after systemic administration. In addition, there are also various strategies to improve cancer-specific replication of OAs, mainly through modifying the early region 1 (E1) of the virus genome. It has been documented that oncolytic viruses (OVs) function through stimulating the immune system, resulting in the inhibition of cancer progression and, in combination with classical immune modulators, the anti-cancer effect of OAs can be even further enforced. To enhance the cancer treatment efficacy, OAs are also combined with other standard treatments, including surgery, chemotherapy and radiotherapy. Adenovirus type 5 (Ad5) has mainly been explored to develop vectors for cancer treatment with different modulations. Only a limited number of the more than 100 identified AdV types were converted into OAs and, therefore, the construction of an adenovirus library for the screening of potential novel OA candidates is essential. Here, we provide a state-of-the-art overview of currently performed and completed clinic trials with OAs and an adenovirus library, providing novel possibilities for developing innovative adenoviral vectors for cancer treatment.<\/jats:p>","DOI":"10.3390\/cancers12051139","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T06:41:20Z","timestamp":1588660880000},"page":"1139","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2830-4810","authenticated-orcid":false,"given":"Jian","family":"Gao","sequence":"first","affiliation":[{"name":"Institute for Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten\/Herdecke University, 58453 Witten, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute for Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten\/Herdecke University, 58453 Witten, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Ehrhardt","sequence":"additional","affiliation":[{"name":"Institute for Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten\/Herdecke University, 58453 Witten, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.1194922","article-title":"Virology. Looking inside adenovirus","volume":"329","author":"Harrison","year":"2010","journal-title":"Science"},{"key":"ref_2","unstructured":"(2020, May 02). HAdV Working Group. Available online: http:\/\/hadvwg.gmu.edu\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1099\/vir.0.000196","article-title":"Human mastadenovirus type 70: A novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient","volume":"96","author":"Hage","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/srep01812","article-title":"Molecular evolution of human adenoviruses","volume":"3","author":"Robinson","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: Implications for targeting of viral vectors","volume":"33","author":"Arnberg","year":"2012","journal-title":"Trends Pharm. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat. Med."},{"key":"ref_7","unstructured":"(2020, May 02). Journal of Gene Medicine. Available online: http:\/\/abedia.com\/wiley\/vectors.php."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/1873-3468.13691","article-title":"State-of-the-art human adenovirus vectorology for therapeutic approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.omtn.2018.12.008","article-title":"Viral Vector-Based Delivery of CRISPR\/Cas9 and Donor DNA for Homology-Directed Repair in an In Vitro Model for Canine Hemophilia B","volume":"14","author":"Gao","year":"2019","journal-title":"Mol. Nucleic Acids"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.gt.3301398","article-title":"Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial","volume":"8","author":"Mulvihill","year":"2001","journal-title":"Gene Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2014.02.034","article-title":"Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer","volume":"89","author":"Freytag","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNalpha Combined with Chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Salazar","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"CT027","DOI":"10.1158\/1538-7445.AM2017-CT027","article-title":"Abstract CT027: Oncolytic virus DNX-2401 with a short course of temozolomide for glioblastoma at first recurrence: Clinical data and prognostic biomarkers","volume":"77","author":"Alonso","year":"2017","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10543","DOI":"10.1200\/JCO.2018.36.15_suppl.10543","article-title":"First-in-child trial of celyvir (autologous mesenchymal stem cells carrying the oncolytic virus ICOVIR-5) in patients with relapsed and refractory pediatric solid tumors","volume":"36","author":"Ramirez","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors\u2014An evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","unstructured":"(2020, April 30). ClinicalTrials.gov: Home, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-04-0765","article-title":"Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model","volume":"10","author":"Tsai","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1006\/mthe.2001.0316","article-title":"Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy","volume":"3","author":"Rahman","year":"2001","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Xu","year":"2013","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","article-title":"Adenovirus-induced thrombocytopenia: The role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance","volume":"109","author":"Othman","year":"2007","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","article-title":"Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1","volume":"113","author":"Carlisle","year":"2009","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nm1297","article-title":"Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells","volume":"11","author":"Cole","year":"2005","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/gt.2009.29","article-title":"Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity","volume":"16","author":"Ilett","year":"2009","journal-title":"Gene Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1158\/0008-5472.CAN-18-3900","article-title":"Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma","volume":"79","author":"Yoon","year":"2019","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41598-019-57240-x","article-title":"Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy","volume":"10","author":"Mahasa","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"655","DOI":"10.5966\/sctm.2013-0039","article-title":"The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma","volume":"2","author":"Tobias","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jnci\/djt141","article-title":"A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy","volume":"105","author":"Ahmed","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1021\/mp200161f","article-title":"A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma","volume":"8","author":"Ahmed","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/mt.2011.100","article-title":"Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma","volume":"19","author":"Ahmed","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6604969","article-title":"Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo","volume":"100","author":"Ulasov","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1158\/0008-5472.CAN-07-6441","article-title":"Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells","volume":"68","author":"Nandi","year":"2008","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/hum.2007.002","article-title":"Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma","volume":"18","author":"Ulasov","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ijc.28450","article-title":"Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites","volume":"134","author":"Jennings","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/0008-5472.CAN-12-3056","article-title":"Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation","volume":"73","author":"Muthana","year":"2013","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ijc.27918","article-title":"Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells","volume":"132","author":"Adair","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/gt.2008.42","article-title":"Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery","volume":"15","author":"Thorne","year":"2008","journal-title":"Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2012.257","article-title":"Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects","volume":"21","author":"Sampath","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/0008-5472.CAN-12-1597","article-title":"Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy","volume":"73","author":"Eisenstein","year":"2013","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e25083","DOI":"10.4161\/onci.25083","article-title":"Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses","volume":"2","author":"Pan","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_43","first-page":"83","article-title":"Immune cells: More than simple carriers for systemic delivery of oncolytic viruses","volume":"3","author":"Eisenstein","year":"2014","journal-title":"Oncolytic Virother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Garofalo, M., Villa, A., Rizzi, N., Kuryk, L., Mazzaferro, V., and Ciana, P. (2018). Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies. Viruses, 10.","DOI":"10.3390\/v10100558"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2018.05.015","article-title":"Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment","volume":"283","author":"Garofalo","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1158\/1078-0432.CCR-06-2532","article-title":"A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy","volume":"13","author":"Leja","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Leja, J., Nilsson, B., Yu, D., Gustafson, E., Akerstrom, G., Oberg, K., Giandomenico, V., and Essand, M. (2010). Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008916"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13114","DOI":"10.1128\/JVI.05759-11","article-title":"Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors","volume":"85","author":"Yu","year":"2011","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000448430","article-title":"Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer","volume":"105","author":"Yu","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/0968-0004(91)90155-O","article-title":"Telomeres","volume":"16","author":"Blackburn","year":"1991","journal-title":"Trends Biochem. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/sj.onc.1202752","article-title":"Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids","volume":"18","author":"Perrem","year":"1999","journal-title":"Oncogene"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/337331a0","article-title":"A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis","volume":"337","author":"Greider","year":"1989","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"32494","DOI":"10.1074\/jbc.M112.368282","article-title":"Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt\/beta-catenin pathway in human cancer","volume":"287","author":"Zhang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3892\/ijo.2015.3047","article-title":"Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA","volume":"47","author":"Gao","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-019-11137-5","article-title":"Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy","volume":"10","author":"Niemann","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_59","first-page":"487","article-title":"A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors","volume":"25","author":"Zhang","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.7150\/jca.18371","article-title":"Upregulation of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung Cancer Cells to CRAd-Induced Inhibition","volume":"8","author":"Sakhawat","year":"2017","journal-title":"J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1038\/s41598-019-43668-8","article-title":"A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma","volume":"9","author":"Sakhawat","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ijc.29048","article-title":"Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma","volume":"136","author":"Siurala","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_67","first-page":"159","article-title":"The regulation of a cellular protein, p53, in normal and transformed cells","volume":"119","author":"Levine","year":"1983","journal-title":"Prog. Clin. Biol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1073\/pnas.91.9.3602","article-title":"p53 and E2F-1 cooperate to mediate apoptosis","volume":"91","author":"Wu","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Blagih, J., Buck, M.D., and Vousden, K.H. (2020). p53, cancer and the immune response. J. Cell Sci., 133.","DOI":"10.1242\/jcs.237453"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"188339","DOI":"10.1016\/j.bbcan.2020.188339","article-title":"BRCA1\/P53: Two strengths in cancer chemoprevention","volume":"1873","author":"Raimundo","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10495-009-0330-1","article-title":"Targeting p53 for enhanced radio- and chemo-sensitivity","volume":"14","author":"Lu","year":"2009","journal-title":"Apoptosis"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrc3711","article-title":"Unravelling mechanisms of p53-mediated tumour suppression","volume":"14","author":"Bieging","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ccell.2017.09.007","article-title":"A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer","volume":"32","author":"Mello","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1089\/hum.2005.16.1014","article-title":"Gendicine: The first commercial gene therapy product","volume":"16","author":"Wilson","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1089\/hum.2005.16.1016","article-title":"Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers","volume":"16","author":"Peng","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2017.00153","article-title":"Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization","volume":"7","author":"Pokrovska","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1074\/jbc.M409934200","article-title":"The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner","volume":"280","author":"Hart","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1128\/JVI.00042-09","article-title":"Temporal regulation of the Mre11-Rad50-Nbs1 complex during adenovirus infection","volume":"83","author":"Karen","year":"2009","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/JVI.01748-10","article-title":"Serotype-specific inactivation of the cellular DNA damage response during adenovirus infection","volume":"85","author":"Forrester","year":"2011","journal-title":"J. Virol."},{"key":"ref_82","first-page":"6053","article-title":"Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene","volume":"54","author":"Kim","year":"1994","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0360-3016(95)00134-9","article-title":"Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents","volume":"33","author":"Kim","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_84","first-page":"53","article-title":"Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene","volume":"2","author":"Khil","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/hum.1997.8.1-73","article-title":"Glioma cells transduced with an Escherichia coli CD\/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity","volume":"8","author":"Rogulski","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"ref_86","first-page":"2081","article-title":"Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy","volume":"3","author":"Rogulski","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_87","first-page":"364","article-title":"Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene","volume":"4","author":"Kim","year":"1998","journal-title":"Cancer J. Sci. Am."},{"key":"ref_88","first-page":"4224","article-title":"Efficacy of adenovirus-mediated CD\/5-FC and HSV-1 thymidine kinase\/ganciclovir suicide gene therapies concomitant with p53 gene therapy","volume":"5","author":"Xie","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_89","first-page":"7497","article-title":"Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer","volume":"63","author":"Freytag","year":"2003","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ymthe.2005.10.005","article-title":"Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity","volume":"13","author":"Barton","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/sj.mt.6300212","article-title":"Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1158\/0008-5472.CAN-05-3033","article-title":"A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy","volume":"66","author":"Boucher","year":"2006","journal-title":"Cancer Res."},{"key":"ref_93","first-page":"4200","article-title":"The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts","volume":"59","author":"Yu","year":"1999","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.cgt.7700835","article-title":"Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity","volume":"12","author":"Dilley","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.cgt.7700555","article-title":"Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein","volume":"10","author":"Toth","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcp.20663","article-title":"Ionizing radiation enhances adenoviral vector expressing mda-7\/IL-24-mediated apoptosis in human ovarian cancer","volume":"208","author":"Emdad","year":"2006","journal-title":"J. Cell Physiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.bjc.6601102","article-title":"Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts","volume":"89","author":"Geoerger","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/09553000010008540","article-title":"Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts","volume":"77","author":"Kawabe","year":"2001","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/1568009617666170502152352","article-title":"Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System","volume":"18","author":"Cerullo","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/sj.onc.1210884","article-title":"Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation","volume":"27","author":"Endo","year":"2008","journal-title":"Oncogene"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00262-015-1683-7","article-title":"Two distinct effector memory cell populations of WT1 (Wilms\u2019 tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients","volume":"64","author":"Nakae","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI200420278","article-title":"Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors","volume":"114","author":"Beckhove","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","article-title":"CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients","volume":"194","author":"Djenidi","year":"2015","journal-title":"J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/1078-0432.CCR-16-0477","article-title":"The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Baker, A.T., Aguirre-Hernandez, C., Hallden, G., and Parker, A.L. (2018). Designer Oncolytic Adenovirus: Coming of Age. Cancers, 10.","DOI":"10.20944\/preprints201805.0273.v1"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e000510","DOI":"10.1136\/esmoopen-2019-000510","article-title":"New emerging targets in cancer immunotherapy: The role of Cluster of Differentiation 40 (CD40\/TNFR5)","volume":"4","author":"Piechutta","year":"2019","journal-title":"ESMO Open"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","article-title":"Clinical and biological effects of an agonist anti-CD40 antibody: A Cancer Research UK phase I study","volume":"21","author":"Johnson","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/1078-0432.CCR-14-0913","article-title":"The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity","volume":"21","author":"Mangsbo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors","volume":"10","author":"Ruter","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1200\/JCO.2001.19.13.3280","article-title":"Phase I study of recombinant human CD40 ligand in cancer patients","volume":"19","author":"Vonderheide","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.smim.2009.07.001","article-title":"The Janus faces of CD40 in cancer","volume":"21","author":"Loskog","year":"2009","journal-title":"Semin. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4049\/jimmunol.158.2.551","article-title":"Costimulation of CD28- T lymphocytes by 4-1BB ligand","volume":"158","author":"DeBenedette","year":"1997","journal-title":"J. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.4049\/jimmunol.168.10.4897","article-title":"4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function","volume":"168","author":"Wen","year":"2002","journal-title":"J. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4049\/jimmunol.167.3.1313","article-title":"4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy","volume":"167","author":"Cannons","year":"2001","journal-title":"J. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-065X.2008.00621.x","article-title":"The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer","volume":"222","author":"Lynch","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3892\/ijo.2015.3005","article-title":"Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21","volume":"47","author":"Li","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/gt.2016.80","article-title":"Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment","volume":"24","author":"Eriksson","year":"2017","journal-title":"Gene Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.gt.3301507","article-title":"Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7 K\/gp19 K region","volume":"8","author":"Hawkins","year":"2001","journal-title":"Gene Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jgm.543","article-title":"Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells","volume":"6","author":"Nilsson","year":"2004","journal-title":"J. Gene Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/hmg\/10.7.699","article-title":"The Rb\/E2F pathway and cancer","volume":"10","author":"Nevins","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/mt.2010.173","article-title":"Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses","volume":"18","author":"Rojas","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: A new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.20.100301.064828","article-title":"Antigen presentation and T cell stimulation by dendritic cells","volume":"20","author":"Guermonprez","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"ref_129","first-page":"127","article-title":"Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients","volume":"7","author":"Nikitina","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4161\/cbt.2.5.440","article-title":"Enhanced adenovirus infection of melanoma cells by fiber-modification: Incorporation of RGD peptide or Ad5\/3 chimerism","volume":"2","author":"Volk","year":"2003","journal-title":"Cancer Biol. Ther."},{"key":"ref_131","first-page":"3812","article-title":"Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy","volume":"62","author":"Rauen","year":"2002","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.1073\/pnas.95.22.13159","article-title":"Adenoviral-mediated gene transfer in lymphocytes","volume":"95","author":"Leon","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1128\/JVI.76.9.4612-4620.2002","article-title":"Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease","volume":"76","author":"Havenga","year":"2002","journal-title":"J. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1128\/JVI.00928-12","article-title":"Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys","volume":"86","author":"Li","year":"2012","journal-title":"J. Virol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm.2267","article-title":"The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis","volume":"17","author":"Nilsson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Lenman, A., Liaci, A.M., Liu, Y., Ardahl, C., Rajan, A., Nilsson, E., Bradford, W., Kaeshammer, L., Jones, M.S., and Frangsmyr, L. (2015). Human adenovirus 52 uses sialic acid-containing glycoproteins and the coxsackie and adenovirus receptor for binding to target cells. Plos Pathog., 11.","DOI":"10.1371\/journal.ppat.1004657"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"14429","DOI":"10.1128\/JVI.79.22.14429-14436.2005","article-title":"CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7","volume":"79","author":"Marttila","year":"2005","journal-title":"J. Virol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","article-title":"Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors","volume":"40","author":"Fishelson","year":"2003","journal-title":"Mol. Immunol."},{"key":"ref_140","first-page":"2311","article-title":"Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners","volume":"27","author":"Yu","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/jgm.1076","article-title":"Improved glioblastoma treatment with Ad5\/35 fiber chimeric conditionally replicating adenoviruses","volume":"9","author":"Hoffmann","year":"2007","journal-title":"J. Gene Med."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Klichinsky, M., Ruella, M., Shestova, O., Lu, X.M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N.R., and Petty, N.E. (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol.","DOI":"10.1038\/s41587-020-0462-y"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., and Fisher, K. (2008). Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002409"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1158\/1535-7163.MCT-15-0819","article-title":"Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer","volume":"15","author":"Liikanen","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0168-1702(94)90054-X","article-title":"Human adenovirus type 41 contains two fibers","volume":"33","author":"Yeh","year":"1994","journal-title":"Virus Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.1128\/JVI.72.10.7909-7915.1998","article-title":"The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F","volume":"72","author":"Roelvink","year":"1998","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1128\/JVI.77.4.2512-2521.2003","article-title":"Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber","volume":"77","author":"Nakamura","year":"2003","journal-title":"J. Virol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1021\/mp0498897","article-title":"Chimeric Ad5 vectors expressing the short fiber of Ad41 show reduced affinity for human intestinal epithelium","volume":"2","author":"Kesisoglou","year":"2005","journal-title":"Mol. Pharm."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4781(02)00249-X","article-title":"Targeted adenoviral vectors","volume":"1575","author":"Barnett","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/hum.2006.132","article-title":"Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma","volume":"18","author":"Hoffmann","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.jid.5701131","article-title":"Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma","volume":"128","author":"Hoffmann","year":"2008","journal-title":"J. Investig. Derm."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/cgt.2011.47","article-title":"Mining the adenovirus virome for oncolytics against multiple solid tumor types","volume":"18","author":"Chen","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1158\/1078-0432.CCR-11-0968","article-title":"Species D adenoviruses as oncolytics against B-cell cancers","volume":"17","author":"Chen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nbt.2183","article-title":"Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting","volume":"30","author":"Fu","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0076-6879(10)77008-7","article-title":"A recombineering pipeline to make conditional targeting constructs","volume":"477","author":"Fu","year":"2010","journal-title":"Methods Enzym."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1089\/hgtb.2018.044","article-title":"Novel Vector Construction Based on Alternative Adenovirus Types via Homologous Recombination","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.celrep.2017.05.008","article-title":"An Engineered Virus Library as a Resource for the Spectrum-wide Exploration of Virus and Vector Diversity","volume":"19","author":"Zhang","year":"2017","journal-title":"Cell Rep."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Abbink, P., Kirilova, M., Boyd, M., Mercado, N., Li, Z., Nityanandam, R., Nanayakkara, O., Peterson, R., Larocca, R.A., and Aid, M. (2018). Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors. J. Virol., 92.","DOI":"10.1128\/JVI.01924-17"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nmeth.1318","article-title":"Enzymatic assembly of DNA molecules up to several hundred kilobases","volume":"6","author":"Gibson","year":"2009","journal-title":"Nat. Methods"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Miciak, J.J., Hirshberg, J., and Bunz, F. (2018). Seamless assembly of recombinant adenoviral genomes from high-copy plasmids. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199563"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e1490856","DOI":"10.1080\/2162402X.2018.1490856","article-title":"CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy","volume":"7","author":"Zafar","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1128\/JVI.78.23.13207-13215.2004","article-title":"Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: Low seroprevalence and non-cross-reactivity with Ad5","volume":"78","author":"Holterman","year":"2004","journal-title":"J. Virol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/cgt.2010.79","article-title":"Oncolytic adenovirus based on serotype 3","volume":"18","author":"Hemminki","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood-2004-02-0646","article-title":"Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells","volume":"104","author":"Leen","year":"2004","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1139\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:25:12Z","timestamp":1760361912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,2]]},"references-count":165,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["cancers12051139"],"URL":"https:\/\/doi.org\/10.3390\/cancers12051139","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,2]]}}}